Editorial Standards

Editorial Methodology

How Peptides Editorial evaluates providers, prices, clinical evidence, pharmacy transparency and consumer terms.

Released: May 27, 2026Last reviewed: July 12, 2026Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · journal · corrections.
EDITORIAL STANDARD

Policy summary

How Peptides Editorial evaluates providers, prices, clinical evidence, pharmacy transparency and consumer terms.

Peptides Editorial is owned and published by US Peptides Partners LLC. Every provider is evaluated under the same published methodology. Providers cannot purchase inclusion, placement, a higher score or an editorial award.

Weighted provider rubric

CategoryWeightWhat earns credit
Clinical oversight25%Named prescribing entity, verifiable clinicians, appropriate screening and follow-up
Pharmacy and medication transparency20%Exact dispensing entity, formulation disclosure and accurate compounded-drug language
Pricing transparency20%Recurring total, fees, dose policy, commitment and cancellation
Safety and regulatory record15%Accurate warnings, adverse-event process and regulator history
Support and continuity10%Response channels, refills, replacement and interruption planning
Accessibility and state coverage10%Accurate state limits, consultation requirements and usability

Missing-data rule

A provider does not receive assumed credit for information that is unavailable. Missing public evidence is scored as unverified, and a provider can be omitted from a ranking even when a service may be legitimate.

Superlative rule

“Cheapest,” “best” and similar awards must name the category, evidence date and constraints. Microdose, standard dose, starter price, medication-only and all-inclusive are separate categories.

Operational standard

This policy is applied through a claim-level evidence ledger. Each material claim records the source, capture date, evidence class, reviewer and the pages that reuse it. Centralizing the record prevents a price or regulatory fact from being updated on one page while remaining stale elsewhere.

Pages are reviewed on a scheduled cadence and whenever a material trigger occurs: an FDA approval or warning, label change, new pivotal trial, shortage-status change, manufacturer pricing update, provider fee change, pharmacy disclosure change or substantiated correction. Cosmetic edits do not reset a clinical-review date.

Peptides Editorial distinguishes three forms of certainty. Verified means the current primary source directly supports the statement. Provider-reported means the company states the fact but additional facility, checkout or third-party confirmation may still be needed. Not normalized means the available evidence is insufficient for a comparative claim; the site does not fill the gap with an estimate.

Publication safeguards

Frequently asked questions

How are factual claims approved?

Claims are checked against the highest available source tier. Regulatory and safety statements use FDA records or official labeling; clinical-outcome statements use peer-reviewed primary research; prices use provider or manufacturer terms with a capture date.

Can a provider review or correct its page?

A provider may submit primary evidence and a written response. Editorial staff verifies the evidence and corrects material errors, but the provider does not approve the conclusion or buy a score.

Does medical review make this personal medical advice?

No. Medical review improves factual and clinical accuracy but does not evaluate an individual reader, create a clinician-patient relationship or replace emergency care.

How is AI used?

Automation may help organize source ledgers, detect inconsistencies and draft structured summaries. Final published claims, tables and conclusions remain subject to human editorial review and the same evidence standard.